BioDelivery Sciences International, Inc. (BDSI)
(Delayed Data from NSDQ)
$4.84 USD
+0.08 (1.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.85 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.84 USD
+0.08 (1.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.85 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
PhaseBio Initiates Phase II Study for Coronavirus Patients
by Zacks Equity Research
PhaseBio (PHAS) initiates phase II study of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome.
Why Is BioDelivery (BDSI) Down 0.4% Since Last Earnings Report?
by Zacks Equity Research
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioDelivery (BDSI) Beats on Q1 Earnings, Withdraws Guidance
by Zacks Equity Research
BioDelivery's (BDSI) strong Belubca sales drive the topline. Symproic further boosts revenues. Stock up.
BioDelivery Sciences International (BDSI) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
BioDelivery (BDSI) delivered earnings and revenue surprises of 400.00% and 15.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
BioDelivery Sciences International (BDSI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioDelivery Sciences International (BDSI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioDelivery (BDSI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BioDelivery (BDSI) beats earnings and sales expectations for the fourth quarter of 2019.
BioDelivery Sciences International (BDSI) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
BioDelivery (BDSI) delivered earnings and revenue surprises of 700.00% and 4.98%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
BioDelivery Sciences International (BDSI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Emmaus (EMMA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors look forward to updates on key drug Endari's expansion plans when Emmaus (EMMA) releases fourth-quarter 2019 results.
Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Alexion (ALXN) beats on earnings and revenues in the fourth quarter of 2019.
Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation
by Zacks Equity Research
Gilead's (GILD) Marketing Authorization Application for KTE-X19 has been fully validated and is now under evaluation with the EMA.
Here's Why You Should Add BioDelivery Stock to Your Portfolio
by Zacks Equity Research
Here are five reasons which make BioDelivery (BDSI)) a good investment option in 2020.
Will Soliris, Ultomiris Drive Alexion's (ALXN) Q4 Earnings?
by Zacks Equity Research
Alexion Inc.'s (ALXN) fourth-quarter 2019 results, scheduled to be reported on Jan 30, are likely to reflect solid performance of key drugs.
What Makes BioDelivery (BDSI) a New Buy Stock
by Zacks Equity Research
BioDelivery (BDSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Flexion's (FLXN) Stock Up on FDA Approval for Zilretta sNDA
by Zacks Equity Research
Flexion's (FLXN) sNDA for osteoarthritis drug, Zilretta, seeking removal of confusing limitation of use label, gets FDA approval.
Are You Looking for a Top Momentum Pick? Why BioDelivery Sciences International (BDSI) is a Great Choice
by Zacks Equity Research
Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
BioDelivery (BDSI) Up 6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What Makes BioDelivery Sciences International (BDSI) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon
by Zacks Equity Research
Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.
Zacks.com featured highlights include: Sciences International, Air Industries, Hallmark Financial Services and Vector
by Zacks Equity Research
Zacks.com featured highlights include: Sciences International, Air Industries, Hallmark Financial Services and Vector
Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU
by Zacks Equity Research
The EMA validates Amarin's (AMRN) regulatory application seeking approval for Vascepa as a treatment to reduce risk of cardiovascular events.
5 Affordable Breakout Stocks for Stunning Returns
by Nitish Marwah
Selecting breakout stocks continues to be one of the most popular methods utilized by active investors.
BioDelivery's Belbuca Sales & Symproic Addition Encouraging
by Zacks Equity Research
BioDelivery's (BDSI) efforts to increase preferred coverage for Belbuca and the acquisition of the rights to Symproic are likely to help continue its momentum.
The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical